ライフサイエンスコーパス: linagliptin

1 same binding site as a diabetic medication, linagliptin.

2 2:1 ratio to once-daily oral treatment with linagliptin 5 mg or matching placebo for 24 weeks.

3 re randomized 1:1 to receive once daily oral linagliptin 5 mg or placebo, on top of standard of care.

4 lly received SIIT for 2-3 weeks, followed by linagliptin 5 mg/day, metformin 1000 mg/day, combination

5 Patients were randomized to receive linagliptin, 5 mg once daily (n = 3494), or placebo once

6 nity-living outpatients were randomised (162 linagliptin, 79 placebo).

7 r and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrol

8 inical trials of the antihyperglycemic drug, linagliptin, a dipeptidyl peptidase 4 inhibitor.

9 We aimed to assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elde

10 In nondiabetic mice, only linagliptin accelerated recovery.

11 type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo ad

12 However, linagliptin and glimepiride recovered the BBB integrity

13 To evaluate the effect of the combination of linagliptin and insulin on metabolic control and prognos

14 3494 (12.4%) and 420 of 3485 (12.1%) in the linagliptin and placebo groups, respectively, (absolute

15 697 (77.2%) and 2723 (78.1%) patients in the linagliptin and placebo groups; 1036 (29.7%) and 1024 (2

16 tolerability were much the same between the linagliptin and placebo groups; 75.9% of patients in bot

17 betics, the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride, which rest

18 drugs: the dipeptidyl peptidase 4 inhibitor linagliptin and the sulfonylurea glimepiride.

19 patients in the linagliptin plus metformin, linagliptin, and metformin group, respectively, achieved

20 patients in the linagliptin plus metformin, linagliptin, and metformin groups, respectively, achieve

21 gous effect, the combined DPP4/FAP inhibitor linagliptin, but not the FAP-specific inhibitor SP-13786

22 and elevated cardiovascular risk, the use of linagliptin compared with glimepiride over a median 6.3

23 trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not

24 ardiovascular disease and/or kidney disease, linagliptin did not affect the risk of hHF or other sele

25 There was no heterogeneity of linagliptin effects on hHF by history of HF at baseline,

26 Mice were treated with linagliptin/glimepiride for 7 weeks.

27 occurred in 320 (10.6%) participants in the linagliptin group and 1132 (37.7%) in the glimepiride gr

28 occurred in 2822 participants (93.4%) in the linagliptin group and 2856 (94.9%) in the glimepiride gr

29 d in 356 of 3023 participants (11.8%) in the linagliptin group and 362 of 3010 (12.0%) in the glimepi

30 nts occurred in 8.6% (14) of patients in the linagliptin group and 6.3% (five) patients in the placeb

31 de group, with 15 participants (0.5%) in the linagliptin group vs 16 (0.5%) in the glimepiride group

32 not differ between groups (24.1% [39] in the linagliptin group, 16.5% [13] in the placebo group; odds

33 Previous studies have shown linagliptin improves beta cell function using animal mod

34 abetic islets, suggesting a positive role of linagliptin in modulating alpha cell function to restore

35 We show pronounced antistroke efficacy of linagliptin in type 2 diabetic and normal mice, whereas

36 termine the potential antistroke efficacy of linagliptin in type 2 diabetic mice.

37 nd hyperglycemia, randomized to receive 5 mg linagliptin + insulin (LI group) or insulin alone (I gro

38 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibito

39 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibito

40 To determine whether linagliptin-mediated efficacy was dependent on a diabeti

41 These results indicate a linagliptin-mediated neuroprotection that is glucose-ind

42 atients in both groups had an adverse event (linagliptin n=123, placebo n=60).

43 Linagliptin normalized T2D-induced angiogenesis and rest

44 Patients were randomized to receive 5 mg of linagliptin once daily (n = 3023) or 1 to 4 mg of glimep

45 roup of HFD-fed mice was treated with either linagliptin or glimepiride for 3 months before sacrifice

46 iptin or placebo in the CARMELINA trial, and linagliptin or glimepiride in the CAROLINA trial.

47 Linagliptin or glimepiride were administered daily from

48 Linagliptin or placebo in the CARMELINA trial, and linag

49 ent oral therapies post-SIIT, especially the linagliptin plus metformin combination, sustainably impr

50 Moreover, the linagliptin plus metformin group showed the most signifi

51 with the control group, participants in the linagliptin plus metformin group were more likely to ach

52 control group (P=0.005 overall; P=0.005 for linagliptin plus metformin versus control; P=0.01 for li

53 e control group (P=0.02 overall; P=0.003 for linagliptin plus metformin versus control; P=0.12 for li

54 (60/88), and 68% (65/95) of patients in the linagliptin plus metformin, linagliptin, and metformin g

55 (63/88), and 73% (69/95) of patients in the linagliptin plus metformin, linagliptin, and metformin g

56 5 mg/day, metformin 1000 mg/day, combination linagliptin plus metformin, or lifestyle modification al

57 sided 95.47% CI for the hazard ratio (HR) of linagliptin relative to glimepiride of less than 1.3.

58 2-sided 95% CI for the hazard ratio (HR) of linagliptin relative to placebo being less than 1.3.

59 Our data showed that linagliptin significantly improved glucose-stimulated in

60 mediates in the lead optimization program of linagliptin, the onset of slow binding kinetics and deve

61 In addition, linagliptin treatment increased the relative GLP-1 vs gl

62 uman islets of T2D patients would respond to linagliptin treatment.

63 hout T2D and evaluated how they responded to linagliptin treatment.

64 in plus metformin versus control; P=0.01 for linagliptin versus control; P=0.008 for metformin versus

65 in plus metformin versus control; P=0.12 for linagliptin versus control; P=0.09 for metformin versus

66 Linagliptin versus placebo did not affect the incidence

67 es with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascu

68 is trial assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea) in patients wi

69 with the aim to establish noninferiority of linagliptin vs glimepiride, defined by the upper limit o

70 Criteria for noninferiority of linagliptin vs placebo was defined by the upper limit of

71 , placebo-adjusted mean change in HbA1c with linagliptin was -0.64% (95% CI -0.81 to -0.48, p<0.0001)

72 In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a s

73 from the standpoint of islet cell function, linagliptin would be more effective in treating early-st